Trethera Announces Jefferies & Company Chairman Emeritus Frank Baxter as Special Advisor

Los Angeles, March 16, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases announces that Frank Baxter has been appointed as special advisor. He will be advising Trethera and its board of directors on financing options including private equity, public equity and debt obligations.

Frank Baxter is Chairman Emeritus of the global investment bank Jefferies & Company Inc. (NYSE: JEF) and served as US Ambassador to Uruguay from November 2006 to January 2009. “We are excited to have Frank participating as a special advisor to our company,” said Dr. Jean DeKernion, President of Trethera. “Ambassador Baxter is among the original outside investors in Trethera. His wealth of experience will be invaluable in exploring the most beneficial financing options for our company and its stockholders as we drive toward clinical trial entry. On behalf of the entire company, we welcome him to the team.”

Ambassador Baxter joined Jefferies in 1974 and became its CEO in 1987 succeeding its founder, Boyd L. Jefferies. Under Baxter’s leadership, the company focused on diversification beyond block equity trading. In the 1990s, he made key decisions to expand Jefferies’ bond trading group as well as increase its investment banking presence. Ambassador Baxter’s push into investment banking led to over $20B capital raised for mid-sized companies. In 2002, he retired as CEO after 14 years in the position. Today Jefferies has over $45B in total assets.

Ambassador Baxter is the former director of the NASD and served as Chairman of the Committee, which resulted in the spin-off of NASDAQ. He subsequently served on the Board of NASDAQ as a member of the Executive Committee and Chairman of the CEO search committee. Ambassador Baxter is also a former director of the Securities Industry Association. He currently participates on numerous boards in Southern California for non-profit organizations and educational institutions, including the St. John’s Health Center Foundation, the University of California Berkeley Foundation and the Los Angeles County Museum of Art. Ambassador Baxter is the recipient of the Bet Tzedek House of Justice Award and the City of Angels award. He graduated from the University of California at Berkeley with a Bachelor of Arts degree in economics.

About Trethera

Trethera is a preclinical stage privately held biopharmaceutical company dedicated to pioneering the development of novel treatments for autoimmune diseases and cancers. Founded by prominent UCLA scientists, Trethera is led by experienced management and board members.

Trethera’s innovative approach to targeting nucleotide metabolism led to the development of TRE-515, an orally taken capsule designated by the FDA as an Orphan Drug. TRE-515 is a first-in-class preclinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors. It is believed that some forms of cancer may be preferentially dependent on the salvage pathway to support tumor growth. Certain autoimmune diseases might respond to TRE-515 treatment. Trethera is developing TRE-515 for use as a monotherapy or in combination, to precisely target a metabolic vulnerability of cancer cells or autoimmune diseases that will transform outcomes for patients.

Note on Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that Trethera believes or anticipates will or may occur in the future are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. Although Trethera has a reasonable basis for the forward-looking statements contained herein, Trethera cautions that such statements are based on current expectations about future events and are subject to risks, uncertainties and factors relating to medical and scientific research, all of which are difficult to predict and many of which are beyond Trethera’s control, that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release. These potential risks and uncertainties include, without limitation: the extent to which development of any novel cancer therapies or therapies for autoimmune diseases succeeds; whether Trethera would obtain the necessary regulatory approvals to commence human trials or commercialize TRE-515 or any novel therapies resulting from such research; Trethera successfully implementing its growth strategy, including that relating to its disease therapies; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; and risks and uncertainties applicable to the business of Trethera. The statements in this press release speak only as of the date hereof and Trethera does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

Trethera Announces Completion of $3.2 Million Seed Funding Round From Current Investors

Los Angeles, February 24, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce completion of its Seed Preferred 3 Stock financing.  Trethera raised an aggregate of $3.2 million from its existing investors, which funds will be used for working capital purposes.

“Raising this amount of capital from current stockholders further signifies Trethera’s momentum, be it from TRE-515 achieving Orphan Drug status or the prosecution of new patents,” said Dr. Kenneth Schultz, Chairman and CEO of Trethera. “Beyond the dollar amount, that many people tend to focus on, are the long-term investors who come with incredible business expertise. Over the past year Trethera has attracted world class talent, with a team of esteemed scientific experts and advisors. Our investors are enthusiastic about Trethera’s multidimensional drug TRE-515 entering clinical trials.”

Trethera’s strategy is to create a highly attractive and differentiated approach for the treatment of cancers and autoimmune diseases with TRE-515. The company is leveraging new insights into metabolic pathways to advance novel treatment strategies. “I am excited by the opportunity to help advance medicines that could significantly impact how people with these diseases are treated,“ concluded Dr. Schultz.

About Trethera

Trethera is a preclinical stage privately held biopharmaceutical company dedicated to pioneering the development of novel treatments for autoimmune diseases and cancers. Founded by prominent UCLA scientists, Trethera is led by experienced management and board members. Trethera’s innovative approach to targeting nucleotide metabolism led to the development of TRE-515, an orally taken capsule designated by the FDA as an Orphan Drug.  TRE-515 is a first-in-class preclinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors.  It is believed that some forms of cancer may be preferentially dependent on the salvage pathway to support tumor growth.  Certain autoimmune diseases might respond to TRE-515 treatment.  Trethera is developing TRE-515 for use as a monotherapy or in combination, to precisely target a metabolic vulnerability of cancer cells or autoimmune diseases that will transform outcomes for patients.

For more information, please visit us at trethera.com.

Note on Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that Trethera believes or anticipates will or may occur in the future are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. Although Trethera has a reasonable basis for the forward-looking statements contained herein, Trethera cautions that such statements are based on current expectations about future events and are subject to risks, uncertainties and factors relating to medical and scientific research, all of which are difficult to predict and many of which are beyond Trethera’s control, that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release. These potential risks and uncertainties include, without limitation: the extent to which development of any novel cancer therapies or therapies for autoimmune diseases succeeds; whether Trethera would obtain the necessary regulatory approvals to commence human trials or commercialize TRE-515 or any novel therapies resulting from such research; Trethera successfully implementing its growth strategy, including that relating to its disease therapies; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; and risks and uncertainties applicable to the business of Trethera. The statements in this press release speak only as of the date hereof and Trethera does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis

Los Angeles, January 7, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515, Trethera’s first-in-class drug for the treatment of acute disseminated encephalomyelitis (ADEM).  ADEM is a rare autoimmune disease where patients lose their nerve function and become paralyzed, causing death in some cases.

“The symptoms of ADEM involve a severe bout of inflammation in the central nervous system that can include the brain, spinal cord, and sometimes the optic nerves. The inflammation damages myelin, the protective substance that coats nerve fibers throughout the central nervous system. No medications have been specifically approved by the FDA to treat it.” said Dr. Peter Clark, a specialist member of the Trethera Scientific Advisory Board. “Holding ODS at this early preclinical stage is a mark of distinction and external validation. The ODS designation qualifies Trethera for certain incentives, which include FDA assistance in designing clinical trials, access to the FDA Orphan Drug Grants Program, exemption from the drug approval application fee and eligibility for seven years of marketing exclusivity.”

About Trethera

Trethera is a preclinical stage privately held biopharmaceutical company dedicated to pioneering the development of novel treatments for autoimmune diseases and cancers. Founded by prominent UCLA scientists, Trethera is led by experienced management and board members. Trethera’s innovative approach to targeting nucleotide metabolism led to the development of TRE-515, an orally taken capsule designated by the FDA as an Orphan Drug.  TRE-515 is a first-in-class preclinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors.  It is believed that some forms of cancer may be preferentially dependent on the salvage pathway to support tumor growth.  Certain autoimmune diseases might respond to TRE-515 treatment.  Trethera is developing TRE-515 for use as a monotherapy or in combination, to precisely target a metabolic vulnerability of cancer cells or autoimmune diseases that will transform outcomes for patients.

Note on Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that Trethera believes or anticipates will or may occur in the future are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. Although Trethera has a reasonable basis for the forward-looking statements contained herein, Trethera cautions that such statements are based on current expectations about future events and are subject to risks, uncertainties and factors relating to medical and scientific research, all of which are difficult to predict and many of which are beyond Trethera’s control, that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release. These potential risks and uncertainties include, without limitation: the extent to which development of any novel cancer therapies or therapies for autoimmune diseases succeeds; whether Trethera would obtain the necessary regulatory approvals to commence human trials or commercialize TRE-515 or any novel therapies resulting from such research; Trethera successfully implementing its growth strategy, including that relating to its disease therapies; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; and risks and uncertainties applicable to the business of Trethera. The statements in this press release speak only as of the date hereof and Trethera does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

Globally Renowned Research Scientist Dr. Michael Shepard Joins Trethera’s Scientific Advisory Board

Los Angeles, December 8, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce that distinguished researcher Michael Shepard, PhD has joined Trethera’s Scientific Advisory Board. Dr. Shepard is a recipient of numerous biotechnology patents and scientific awards for his contributions to the development of innovative therapies including the prestigious Lasker-DeBakey Clinical Medical Research Award in 2019. Founded in 1945, the Lasker-DeBakey award is widely regarded as a top global biomedical research prize.

“We are honored to have Dr. Shepard join Trethera’s Scientific Advisory Board. Dr. Shepard is an internationally recognized industry pioneer who has helped develop breakthrough autoimmune and cancer therapies such as Herceptin,” said Dr. Kenneth Schultz, Chairman and CEO of Trethera. “Dr. Shepard joins us at an exciting time as we continue to develop TRE-515, our first-in-class dCK inhibitor for multiple indications. He has deep experience expanding cancer drugs to treat inflammatory and autoimmune diseases”.

Dr. Shepard, currently the President and CEO of Enosi Life Sciences, is best known for his pioneering work at Genetech where he led the team that discovered the antibody that attacks HER2-tumor cells that later became known as Herceptin. Herceptin is a life-saving therapy for women with breast cancer, reducing the risk of recurrence while extending survival times. While still at Genetech, Dr. Shepard also collaborated with fellow renowned researcher Sir Marc Feldmann, to develop Remicade, a TNF inhibitor now used to treat multiple autoimmune diseases. Dr. Shepard is also a recipient of the Warren Alpert Foundation Prize from the Harvard Medical School, a significant award given to scientists whose achievements have led to the prevention, cure or treatment of human diseases.

“At this juncture in my career I continually have the opportunity to be selective and work on therapies that show promise. I am very excited to be chosen to work with the Trethera team,” said Dr. Shepard. “I have found that Trethera’s small molecule inhibitor of deoxycytidine kinase, TRE-515, is an encouraging development with the potential to treat autoimmune diseases such as multiple sclerosis and certain forms of cancer. I look forward to lending expertise and advising them on their path toward clinical trials.”

About Trethera

Trethera is a preclinical stage privately held biopharmaceutical company dedicated to pioneering the development of novel treatments for autoimmune diseases and cancers. Founded by prominent UCLA scientists, Trethera is led by experienced management and board members. Trethera’s innovative approach to targeting nucleotide metabolism led to the development of TRE-515, an orally taken capsule. TRE-515 is a first-in-class preclinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors. It is believed that some forms of cancer may be preferentially dependent on the salvage pathway to support tumor growth. Certain autoimmune diseases might respond to TRE-515 treatment. Trethera is developing TRE-515 for use as a monotherapy or in combination, to precisely target a metabolic vulnerability of cancer cells or autoimmune diseases that will transform outcomes for patients.

Note on Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that Trethera believes or anticipates will or may occur in the future are “forward-looking statements” which may often, but not always, be identified by the use of such words as “may”, “might”, “will”, “will likely result”, “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek,” “continue”, “target” or the negative of such terms or other similar expressions. Although Trethera has a reasonable basis for the forward-looking statements contained herein, Trethera cautions that such statements are based on current expectations about future events and are subject to risks, uncertainties and factors relating to medical and scientific research, all of which are difficult to predict and many of which are beyond Trethera’s control, that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release. These potential risks and uncertainties include, without limitation: the extent to which development of any novel cancer therapies or therapies for autoimmune diseases succeeds; whether Trethera would obtain the necessary regulatory approvals to commence human trials or commercialize TRE-515 or any novel therapies resulting from such research; Trethera successfully implementing its growth strategy, including that relating to its disease therapies; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; and risks and uncertainties applicable to the business of Trethera. The statements in this press release speak only as of the date hereof and Trethera does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

Trethera Announces U.S. Patent Application Filed for TRE-515, Extending Major Markets Exclusivity until 2041

Los Angeles, November 2, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases is pleased to announce that it has filed a provisional patent application with the US Patent & Trademark Office for the company’s first-in-class drug TRE-515.  If granted, the patent will provide global market exclusivity until 2041. The company’s outside intellectual property (IP) counsel Wilson Sonsini Goodrich & Rosati led the prosecution. 

“As part of our comprehensive IP strategy, the filling of the provisional patent is an important step in Trethera’s mission to build stockholder value even at this early stage of drug development,” said Dr. Kenneth Schultz, Chairman and CEO of Trethera. “When granted, the patent will add an additional six to seven years of market exclusivity and will be wholly owned by Trethera.”  The patent claims cover the unique TRE-515 chemical structure, whether in the treatment of cancer, autoimmune, or other diseases.   “It is anticipated that the granting of the new patent will have broad applicability and provide coverage in most countries,” added Dr. Schultz, “including the major pharmaceutical markets of the US, Europe, and Japan.”

Trethera anticipates that it will have opportunities to file additional patents over the next 12-24 months. “The filing of the provisional patent puts us in a strong position to further enhance the IP protection for TRE-515.  A well-designed patent strategy can assist drug companies, like Trethera, recoup their substantial research and development expenses and product launch costs,” concluded Dr. Schultz.

About Trethera

Trethera is a preclinical stage privately held biopharmaceutical company dedicated to pioneering the development of novel treatments for autoimmune diseases and cancers. Founded by prominent UCLA scientists, Trethera is led by experienced management and board members. Trethera’s innovative approach to targeting nucleotide metabolism led to the development of TRE-515, an orally taken capsule.  TRE-515 is a first-in-class preclinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors.  It is believed that some forms of cancer may be preferentially dependent on the salvage pathway to support tumor growth.  Certain autoimmune diseases might respond to TRE-515 treatment.  Trethera is developing TRE-515 for use as a monotherapy or in combination, to precisely target a metabolic vulnerability of cancer cells or autoimmune diseases that will transform outcomes for patients.

Note on Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that Trethera believes or anticipates will or may occur in the future are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. Although Trethera has a reasonable basis for the forward-looking statements contained herein, Trethera cautions that such statements are based on current expectations about future events and are subject to risks, uncertainties and factors relating to medical and scientific research, all of which are difficult to predict and many of which are beyond Trethera’s control, that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release. These potential risks and uncertainties include, without limitation: the extent to which development of any novel cancer therapies or therapies for autoimmune diseases succeeds; whether Trethera would obtain the necessary regulatory approvals to commence human trials or commercialize TRE-515 or any novel therapies resulting from such research; Trethera successfully implementing its growth strategy, including that relating to its disease therapies; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; and risks and uncertainties applicable to the business of Trethera. The statements in this press release speak only as of the date hereof and Trethera does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

Trethera Corporation announces appointment of Timothy “Tim” Donahue, M.D. to the Board of Directors 


Los Angeles, January 31, 2019 /PRNewswire/ —

Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer, announced the nomination and acceptance of Timothy Donahue to Trethera’s Board of Directors by unanimous vote of the Board. 

“I am delighted to have Dr. Donahue join the Trethera Board of Directors.  Dr. Donahue brings a wealth of medical experience, especially within gastrointestinal tumors, and will be a valuable addition as Trethera continues to advance towards clinical oncology trials in solid tumors,” said Trethera co-founder Owen Witte, M.D.

Dr. Donahue is Chief of the Division of Surgical Oncology and Professor of Surgery at the David Geffen School of Medicine at UCLA. He also has a joint appointment in the Department of Molecular and Medical Pharmacology to facilitate his research program. In addition to his clinical work, Dr. Donahue is the Principal Investigator of a National Institutes of Health funded research laboratory.

“Having Tim join Trethera is a real plus, his medical laboratory is fully integrated with our founders’ laboratories and his expertise helps us start the translation of preclinical experiments into an optimized clinical trial design,” said Kenneth A. Schultz, M.D., Trethera’s Chairman and Chief Executive Officer. “Our team is excited to add Dr. Donahue at this pivotal time in the company.”

Dr. Donahue’s scientific research focuses on developing new drugs and better treatment strategies, collaborating with numerous other researchers worldwide.  He is also dedicated to training the next generation of academic surgeons and serves as the Program Director of the UCLA General Surgery Residency.

“I’m excited to join a UCLA biopharmaceutical spinout company dedicated to helping cancer patients overcome their disease,” said Dr. Tim Donahue, “translating the early, but promising, preclinical results of TRE-515 into compelling clinical evidence will be a priority.”

Founded by highly regarded UCLA faculty, Trethera focuses on pathways controlling cancer nucleotide metabolism. TRE-515, a first-in-class inhibitor of deoxycytidine kinase (dCK), is an orally administered small molecule that has demonstrated activity in preclinical models treating a variety of tumors, both in monotherapy and when in combination with certain FDA approved drugs. 

About TRE-515

TRE-515 is a first-in-class preclinical drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the deoxyribonucleoside salvage pathway, one of two biosynthetic pathways that generate the DNA precursors, the other being the de novo pathway. Certain cancer cells may appear preferentially dependent on the salvage pathway for nucleotides to support tumor growth. Trethera has developed TRE-515 for use as monotherapy or in combination with de novo pathway inhibitors, to precisely target a metabolic vulnerability of these cancer cells. This approach holds the potential to improve treatment efficacy and minimize the development of drug resistance.

About Trethera Corporation

Trethera is a privately-held biopharmaceutical company dedicated to developing novel treatments for cancers with high unmet needs. For more information, visit trethera.com.

Press Contact:

Martin Eglitis, PhD

Meglitis@trethera.com

Note on Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that Trethera believes or anticipates will or may occur in the future are forward-looking statements. Although Trethera has a reasonable basis for the forward-looking statements contained herein, Trethera cautions that such statements are based on current expectations about future events and are subject to risks, uncertainties and factors relating to medical research, all of which are difficult to predict and many of which are beyond Trethera’s control, that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, the extent to which development of any novel cancer therapies succeeds; and whether Trethera would obtain the necessary regulatory approvals to commence human trials or commercialize TRE-515 or any novel therapies resulting from such research. The statements in this press release speak only as of the date hereof and Trethera does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise.

Trethera Corporation and KYAN Therapeutics announce collaboration to develop artificial intelligence-driven optimization of solid cancer combination therapy

Los Angeles//Singapore, October 25, 2018 /PRNewswire/ — 

Trethera Corporation (Trethera),a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer,and KYAN Therapeutics, an artificial intelligence-based drug development firm, announced an agreement to collaborate on preclinical studies evaluating up to four different tumor types beginning this year leveraging their unique expertise to develop best-in-class combination therapies addressing unmet needs in solid tumors.

 

Under the agreement both companies will evaluatethe solid tumor responses to various novel combination therapies and dosing seen with Trethera’s compound TRE-515.  “This venture  helps Trethera to intelligently and efficiently explore the utility of our IND approved drug TRE-515 across a wide range of tumors, doses, and drug combinations” said Kenneth A. Schultz, M.D., Trethera’s Executive Chairman. “Our team is excited about developing the first therapeutic to target the salvage pathway of nucleotide synthesis, a metabolic pathway that may contribute to the progression of a variety of tumors.”

 

Founded by highly regarded UCLA faculty, Trethera focuses on pathways controlling cancer nucleotide metabolism.  TRE-515, a first-in-class inhibitor of deoxycytidine kinase (dCK), is an orally administered small molecule that has demonstrated activity in preclinical models treating a variety of tumors, both in monotherapy and when in combination with certain FDA approved drugs.

 

KYAN was initiated by a team of visionary leaders from NUS and UCLA that has successfully taken its proprietary portfolio of AI platforms through clinical validation. By uniquely demonstrating that globally optimized efficacy and safety can be achieved at each stage of drug development, from in vitrothrough preclinical and clinical validation, KYAN’s technology systematically identifies AI-driven novel drug combinations that are realized independently from conventional approaches. KYAN’s deterministic approach has led to scientific success within multiple indications tackled to date, in globally optimizing drug combinations for both composition and dosage. As such, KYAN collaborations may accelerate a biopharma company’s pathway towards first-in-man studies.

 

“KYAN is thrilled to be embarking alongside Trethera on this exciting collaboration ,” said Dean Ho, Ph.D., KYAN Co-Founder. ” Trethera’s research team has deep experience within DNA synthesis pathways and oncology therapeutic discoveries.  Combining TRE-515 with KYAN’s powerful AI optimization platforms may lead to best-in-class drug combinations that improve solid cancer treatments,” added Ho.

 

 

About TRE-515

TRE-515 is a first-in-class preclinical drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the deoxyribonucleoside salvage pathway, one of two biosynthetic pathways that generate the DNA precursors, the other being the de novopathway.  Certain cancer cells may appear preferentially dependent on the salvage pathway for nucleotides to support tumor growth. Trethera has developed TRE-515 for use as monotherapy or in combination with de novo pathway inhibitors, to precisely target a metabolic vulnerability of these cancer cells. This approach holds the potential to improve treatment efficacy and minimize the development of drug resistance.

 

About Trethera Corporation

Trethera is a privately-held biopharmaceutical company dedicated to developing novel treatments for cancers with high unmet needs. For more information, visit trethera.com.

 

About KYAN Therapeutics, Inc.

KYAN Therapeutics is a clinical-stage artificial intelligence company leveraging its proprietary technology platforms to transform the way patients are treated and therapies are developed. KYAN is able to revolutionize the drug development and dosage optimization processes and has multiple pipeline combination therapies in development for oncology and infectious diseases. KYAN de-risks and  dramatically accelerates the drug development process, identifying novel combination therapies with unprecedented efficacy and safety. KYAN’s clinically-validated platforms are uniquely disease mechanism and indication agnostic.

 

 

Press Contacts:

 

Trethera Corporation

Martin Eglitis, PhD

Meglitis@trethera.com

 

KYAN Therapeutics, Inc.

Shane Low

shane@kyantherapeutics.com

 

Note on Forward-Looking Statements

 

All statements other than statements of historical facts included in this press release that address activities, events or developments that Trethera or KYAN  expect, believe or anticipate will or may occur in the future are forward-looking statements. Although Trethera and KYAN believe that Trethera and KYAN have a reasonable basis for the forward-looking statements contained herein, Trethera and KYAN caution that such statements are based on current expectations about future events and are subject to risks, uncertainties and factors relating to medical research, all of which are difficult to predict and many of which are beyond their control, that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, the extent to which the joint research to be conducted by Trethera and KYAN pursuant to the Development Collaboration Agreement will result in the development of any novel cancer therapies; and whether Trethera would obtain the necessary regulatory approvals to commence human trials or commercialize TRE-515 or any novel therapies resulting from such research. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. Trethera and KYAN do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.